SHREWSBURY, Mass., June 22 /PRNewswire-FirstCall/ -- TranXenoGen, Inc.
("TranXenoGen" or the "Company"), announced today that the United States
Patent and Trademark Office has issued a patent (No. 6,753,457) covering a
method of reprogramming somatic cell nuclei for the production of cloned
animals or embryos using nuclear transfer techniques. The technique, which is
a key step in the cloning process, has broad applications in human
therapeutics and agriculture, including the production of biopharmaceuticals
in transgenic animals, generation of organs for xenotransplantation and the
development of stem cell lines.
TranXenoGen is the exclusive licensee of the US patent, which issued to
Brandeis University. The patent entitled "Nuclear Reprogramming Using
Cytoplasmic Extract" is one of five issued patents licensed to the Company
covering the nuclear reprogramming technology. The Company is seeking to out-
license the technology in several key areas such as stem cell research,
livestock and pet cloning as well as to establish research collaborations to
aid in the commercialization of the technology.
Mr. George Uveges stated that, "As we outlined in our 2003 Annual Report,
the Company's short-term revenue focus includes the marketing of the Company's
patent portfolio. The issuance of this cloning patent is a significant step
in enhancing the value of and monetizing the Company's patent portfolio."
Risk Warning Notice:
TranXenoGen, Inc. (LSE: TXN.L ) is a publicly traded development stage,
biotechnology company that is focused on developing new therapeutic production
technologies and products. Its shares are quoted on the Alternative
Investment Market of the London Stock Exchange. The securities of the Company
have not been registered under the Securities Act of 1933 and therefore, may
not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements under such Act.
TranXenoGen is a development stage company and, as such, investors should
be aware that an investment in the Company involves a substantially high
degree of risk.
This press release contains forward-looking statements that can be
identified by terminology such as "expects", "potential", "suggests", "may",
"will" or similar expressions. Such forward-looking statements regarding our
business, which are not historical facts, are "forward-looking statements"
that involve risk and uncertainties, which could cause the Company's actual
results and financial condition to differ materially from those anticipated by
the forward-looking statements. Actual results may differ materially from
statements made as a result of various factors, including, but not limited to
sufficiency of cash to fund the Company's planned operations, risk associated
with inherent uncertainty of product research and development, risk of
protecting proprietary rights and competition. Forward-looking statements
speak only as to the date they are made. The Company does not undertake to
update forward-looking statements to reflect the circumstances or events that
occur after the date the forward-looking statements are made.
Contact:
TranXenoGen, Inc.
Tel: 001 508 936 4214
George Uveges, President and CEO
800 Boston Turnpike
Shrewsbury, MA 01545
Email: guveges@tranxenogen.com\
SOURCE TranXenoGen, Inc.
 back to top
Related links:
http://www.tranxenogen.com
CONTACT:
George Uveges, President and CEO of
TranXenoGen, Inc., 001 508 936 4214, guveges@tranxenogen.com
|
